EDITAS MEDICINE, INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
EDITAS MEDICINE, INC. (EDIT) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$6.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2026-08-05
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-06-30 was -$6.00K.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-03-31 was $0.00.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-12-31 was $0.00.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-09-30 was -$15.00K, a 101.56% decline year-over-year.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2025 was -$268.00K, a 482.86% decline from fiscal 2024.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2024 was $70.00K, a 98.16% decline from fiscal 2023.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2023 was $3.80M.
- EDITAS MEDICINE, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2022 was -$3.11M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$6.00K 10-Q · filed 2026-08-05 | -$6.00K 10-Q · filed 2026-08-05 | -$6.00K derived: sum of 3 quarters · filed 2026-08-05 | -$21.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | -$15.00K derived: sum of 3 quarters · filed 2026-05-05 | -$88.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$15.00K derived: sum of 2 quarters · filed 2026-03-09 | -$88.00K derived: sum of 3 quarters · filed 2026-08-05 | -$268.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | -$15.00K 10-Q · filed 2025-11-10 | -$88.00K derived: sum of 2 quarters · filed 2026-08-05 | -$268.00K 10-Q · filed 2025-11-10 | -$522.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$73.00K 10-Q · filed 2026-08-05 | -$253.00K 10-Q · filed 2026-08-05 | -$507.00K derived: sum of 3 quarters · filed 2026-08-05 | $457.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$180.00K 10-Q · filed 2026-08-05 | -$434.00K derived: sum of 2 quarters · filed 2026-08-05 | $530.00K derived: sum of 3 quarters · filed 2026-08-05 | $414.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2024-12-31 | -$254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $710.00K derived: sum of 2 quarters · filed 2026-03-09 | $594.00K derived: sum of 3 quarters · filed 2026-03-09 | $70.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $964.00K 10-Q · filed 2025-11-10 | $848.00K derived: sum of 2 quarters · filed 2025-11-10 | $324.00K 10-Q · filed 2025-11-10 | $1.97M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$116.00K 10-Q · filed 2025-11-10 | -$640.00K 10-Q · filed 2025-08-12 | $1.01M derived: sum of 3 quarters · filed 2025-11-10 | $1.84M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-03-31 | -$524.00K 10-Q · filed 2025-11-10 | $1.13M derived: sum of 2 quarters · filed 2025-11-10 | $1.96M derived: sum of 3 quarters · filed 2025-11-10 | $1.95M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2023-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $2.48M derived: sum of 2 quarters · filed 2025-03-05 | $2.48M derived: sum of 3 quarters · filed 2025-03-05 | $3.80M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $833.00K 10-Q · filed 2024-11-04 | $827.00K derived: sum of 2 quarters · filed 2024-11-04 | $2.15M 10-Q · filed 2024-11-04 | $2.84M derived: sum of 4 quarters · filed 2025-03-05 | |
| 2023-06-30 | -$6.00K 10-Q · filed 2024-11-04 | $1.32M 10-Q · filed 2024-08-07 | $2.01M derived: sum of 3 quarters · filed 2025-03-05 | $1.10M derived: sum of 4 quarters · filed 2025-03-05 | |
| 2023-03-31 | $1.32M 10-Q · filed 2024-11-04 | $2.01M derived: sum of 2 quarters · filed 2025-03-05 | $1.11M derived: sum of 3 quarters · filed 2025-03-05 | $230.00K derived: sum of 4 quarters · filed 2025-03-05 | |
| 2022-12-31 | $690.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$214.00K derived: sum of 2 quarters · filed 2025-03-05 | -$1.09M derived: sum of 3 quarters · filed 2025-03-05 | -$3.11M 10-K · filed 2025-03-05 | |
| 2022-09-30 | -$904.00K 10-Q · filed 2023-11-03 | -$1.78M derived: sum of 2 quarters · filed 2023-11-03 | -$3.80M 10-Q · filed 2023-11-03 | -$4.23M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | -$878.00K 10-Q · filed 2023-11-03 | -$2.89M 10-Q · filed 2023-08-02 | -$3.32M derived: sum of 3 quarters · filed 2024-02-28 | -$3.32M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | -$2.02M 10-Q · filed 2023-11-03 | -$2.44M derived: sum of 2 quarters · filed 2024-02-28 | -$2.44M derived: sum of 3 quarters · filed 2024-02-28 | -$2.44M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$422.00K derived: sum of 2 quarters · filed 2024-02-28 | -$420.00K derived: sum of 3 quarters · filed 2024-02-28 | -$447.00K 10-K · filed 2024-02-28 | |
| 2021-09-30 | $7.00K 10-Q · filed 2022-11-02 | $9.00K derived: sum of 2 quarters · filed 2022-11-02 | -$18.00K 10-Q · filed 2022-11-02 | -$16.00K derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | $2.00K 10-Q · filed 2022-08-03 | -$25.00K 10-Q · filed 2022-08-03 | -$23.00K derived: sum of 3 quarters · filed 2023-02-22 | -$254.00K derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | -$27.00K 10-Q · filed 2022-05-04 | -$25.00K derived: sum of 2 quarters · filed 2023-02-22 | -$256.00K derived: sum of 3 quarters · filed 2023-02-22 | -$767.00K derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$229.00K derived: sum of 2 quarters · filed 2023-02-22 | -$740.00K derived: sum of 3 quarters · filed 2023-02-22 | -$153.00K 10-K · filed 2023-02-22 | |
| 2020-09-30 | -$231.00K 10-Q · filed 2021-11-09 | -$742.00K derived: sum of 2 quarters · filed 2021-11-09 | -$155.00K 10-Q · filed 2021-11-09 | -$87.00K derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | -$511.00K 10-Q · filed 2021-08-05 | $76.00K 10-Q · filed 2021-08-05 | $144.00K derived: sum of 3 quarters · filed 2022-02-24 | $138.00K derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $587.00K 10-Q · filed 2021-05-06 | $655.00K derived: sum of 2 quarters · filed 2022-02-24 | $649.00K derived: sum of 3 quarters · filed 2022-02-24 | $665.00K derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $62.00K derived: sum of 2 quarters · filed 2022-02-24 | $78.00K derived: sum of 3 quarters · filed 2022-02-24 | $136.00K 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$6.00K 10-Q · filed 2020-11-06 | $10.00K derived: sum of 2 quarters · filed 2020-11-06 | $68.00K 10-Q · filed 2020-11-06 | $121.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | $16.00K 10-Q · filed 2020-08-07 | $74.00K 10-Q · filed 2020-08-07 | $127.00K derived: sum of 3 quarters · filed 2021-02-26 | $44.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | $58.00K 10-Q · filed 2020-05-08 | $111.00K derived: sum of 2 quarters · filed 2021-02-26 | $28.00K derived: sum of 3 quarters · filed 2021-02-26 | $81.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$30.00K derived: sum of 2 quarters · filed 2021-02-26 | $23.00K derived: sum of 3 quarters · filed 2021-02-26 | $47.00K 10-K · filed 2021-02-26 | |
| 2018-09-30 | -$83.00K 10-Q · filed 2019-11-12 | -$30.00K derived: sum of 2 quarters · filed 2019-11-12 | -$6.00K 10-Q · filed 2019-11-12 | -$59.00K derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-06-30 | $53.00K 10-Q · filed 2019-08-07 | $54.00K 10-Q · filed 2018-08-07 | $77.00K 10-Q · filed 2019-08-07 | $24.00K derived: sum of 3 quarters · filed 2020-02-26 | $68.00K derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $24.00K 10-Q · filed 2019-05-08 | -$52.00K 10-Q · filed 2018-05-04 | -$29.00K derived: sum of 2 quarters · filed 2020-02-26 | $15.00K derived: sum of 3 quarters · filed 2020-02-26 | -$52.00K derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | -$53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$9.00K derived: sum of 2 quarters · filed 2020-02-26 | -$76.00K derived: sum of 3 quarters · filed 2020-02-26 | -$76.00K 10-K · filed 2020-02-26 | |
| 2017-09-30 | $44.00K 10-Q · filed 2018-11-08 | -$23.00K derived: sum of 2 quarters · filed 2018-11-08 | -$23.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$67.00K 10-Q · filed 2018-08-07 | -$67.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |